

**STATE OF MICHIGAN  
MICHIGAN ADMINISTRATIVE HEARING SYSTEM  
FOR THE DEPARTMENT OF COMMUNITY HEALTH**

P.O. Box 30763, Lansing, MI 48909  
(877) 833-0870; Fax: (517) 373-4147

**IN THE MATTER OF:**

██████████,

Appellant

---

Docket No. 2013-38787 PHR

Case No. ██████████

**DECISION AND ORDER**

This matter is before the undersigned Administrative Law Judge pursuant to MCL 400.9 and 42 CFR 431.200 *et seq.*, upon the Appellant's request for a hearing.

After due notice, a hearing was held on ██████████. The Appellant appeared without representation. He had no witnesses. The Department was represented by ██████████, PhR, Manager. She had no witnesses.

**ISSUE**

Did the Department properly deny Appellant's request for prior authorization (PA) of Adderall XR?

**FINDINGS OF FACT**

The Administrative Law Judge, based upon the competent, material and substantial evidence on the whole record, finds as material fact:

1. Appellant is a ██████-year-old male Medicaid beneficiary, born ██████████. (Exhibit 1; Testimony)
2. Appellant is afflicted with ADD. (Exhibit 1; Testimony)
3. On ██████████, Appellant's physician, a family practice practitioner, submitted a PA for the product Adderall XR for a diagnosis of ADD for Appellant. (Exhibit A, p. 5)
4. Appellant reported that he needs Adderall to be able to concentrate in school, and to keep his train of thought on path so he can stay organized enough to attend all of his doctor appointments and physical therapy. Appellant also indicated that he has tried other medications but none have

worked. Appellant indicated that Adderall XR helps him stay focused when driving to his numerous doctor appointments. (Exhibit 1; Testimony)

5. Owing to contractual requirements between Magellan Medicaid Administration (MMA) and the Michigan Department of Community Health the request for Adderall XR was reviewed for clinical compliance by MSA Medical Reviewer, Dr. ██████████, M.D. – who denied the request for lack of supporting documentation for the diagnosis of adult with interrupted treatment and for lack of an adult mental health evaluation. (Exhibit A, p 26; Testimony)
6. Appellant and the prescriber were notified of the denial. (Exhibit A, p 27)
7. The Appellant was notified in writing of his further appeal rights via adequate action/denial of service on ██████████. (Exhibit A, p 28)
8. The instant request for hearing was received by the Michigan Administrative Hearing System on ██████████. (Exhibit 1)

### **CONCLUSIONS OF LAW**

The Medical Assistance Program is established pursuant to Title XIX of the Social Security Act and is implemented by Title 42 of the Code of Federal Regulations (CFR). It is administered in accordance with state statute, the Social Welfare Act, the Administrative Code, and the State Plan under Title XIX of the Social Security Act Medical Assistance Program.

Social Security Act § 1927(d), [42 USC 1396r-8(d)]

#### **LIMITATIONS ON COVERAGE OF DRUGS --**

##### **(1) PERMISSIBLE RESTRICTIONS –**

- (A) A state may subject to prior authorization any covered outpatient drug. Any such prior authorization program shall comply with the requirements of paragraph (5).

A state may exclude or otherwise restrict coverage of a covered outpatient drug if –

- (i) the prescribed use is not for a medically accepted indication (as defined in subsection (k)(6);
- (ii) the drug is contained in the list referred to in paragraph (2);

- (iii) the drug is subject to such restriction pursuant to an agreement between a manufacturer and a State authorized by the Secretary under subsection (a)(1) or in effect pursuant to subsection (a)(4); or
- (iv) the State has excluded coverage of the drug from its formulary in accordance with paragraph 4.

(4) REQUIREMENTS FOR FORMULARIES - A State may establish a formulary if the formulary meets the following requirements:

- (A) The formulary is developed by a committee consisting of physicians, pharmacists, and other appropriate individuals appointed by the Governor of the State (or, at the option of the State, the State's drug use review board established under subsection (g)(3)).
- (B) Except as provided in subparagraph (C), the formulary includes the covered outpatient drugs of any manufacturer, which has entered into and complies with an agreement under subsection (a) (other than any drug excluded from coverage or otherwise restricted under paragraph (2)).
- (C) A covered outpatient drug may be excluded with respect to the treatment of a specific disease or condition for an identified population (if any) only if, based on the drug's labeling (or, in the case of a drug the prescribed use of which is not approved under the Federal Food, Drug, and Cosmetic Act but is a medically accepted indication, based on information from appropriate compendia described in subsection (k)(6)), the excluded drug does not have a significant, clinically meaningful therapeutic advantage in terms of safety, effectiveness, or clinical outcome of such treatment for such population over other drugs included in the formulary and there is a written explanation (available to the public) of the basis for the exclusion.
- (D) The state plan permits coverage of a drug excluded from the formulary (other than any drug excluded from coverage or otherwise restricted under paragraph (2)) pursuant to a prior authorization program that is consistent with paragraph (5),

- (E) The formulary meets such other requirements as the Secretary may impose in order to achieve program savings consistent with protecting the health of program beneficiaries.

A prior authorization program established by a State under paragraph (5) is not a formulary subject to the requirements of this paragraph.

(5) REQUIREMENTS OF PRIOR AUTHORIZATION PROGRAMS. — A State plan under this title may require, as a condition of coverage or payment for a covered outpatient drug for which Federal financial participation is available in accordance with this section, with respect to drugs dispensed on or after July 1, 1991, the approval of the drug before its dispensing for any medically accepted indication (as defined in subsection (k)(6)) only if the system providing for such approval –

- (A) Provides response by telephone or other telecommunication device within 24 hours of a request for prior authorization; and  
(B) Except with respect to the drugs referred to in paragraph (2) provides for the dispensing of at least 72-hour supply of a covered outpatient prescription drug in an emergency situation (as defined by the Secretary).

(6) OTHER PERMISSIBLE RESTRICTIONS – A State may impose limitations, with respect to all such drugs in a therapeutic class, on the minimum or maximum quantities per prescription or on the number of refills, if such limitations are necessary to discourage waste, and may address instances or fraud or abuse by individuals in any manner authorized under this Act.

Furthermore, the Medicaid Provider Manual (MPM) sets forth significant criteria for documentation of unusual off-label uses and prior authorization requests:

#### **DOCUMENTATION REQUIREMENTS**

For all requests for PA, the following documentation is required:

- Pharmacy name and phone number;
- Beneficiary diagnosis and medical reason(s) why another covered drug cannot be used;
- Drug name, strength, and form;
- Other pharmaceutical products prescribed;
- Results of therapeutic alternative medications tried; and

- MedWatch Form or other clinical information may be required.

### **PRIOR AUTHORIZATION DENIALS**

PA denials are conveyed to the requester. PA is denied if:

- The medical necessity is not established.
- Alternative medications are not ruled out.
- Evidence-based research and compendia do not support it.
- It is contraindicated, inappropriate standard of care.
- It does not fall within MDCH clinical review criteria.
- Documentation required was not provided.

(Emphasis supplied)

MPM, Pharmacy §§8.4, 8.6, pages 15 and 16, April 1, 2013.<sup>1</sup>

\*\*\*

The Department witness testified that the requested drug was designed to help treat ADD/ADHD. She added that a request involving interrupted treatment when the patient has reached 18-years of age requires additional documentation and clinical evaluation from a psychiatrist, a clinical psychologist or a clinical social worker. She said that additional information was requested of the prescriber – but no information was received prior to hearing. She testified that owing to contractual requirements the request was forwarded to MDCH MSA physician reviewer, Dr. ██████████ who conducted her review and concluded that the PA would be denied for lack of supporting documentation and proof of evaluation from a psychiatrist, clinical psychologist or clinical social worker that supports the diagnosis of ADD for an adult with interrupted treatment.

The Appellant testified that he understood what was required of him and actually had an appointment set up for an evaluation within the next week.

The Department's evidence clearly showed that the Appellant had not satisfied the Medicaid criteria for renewed approval of Adderall XR – owing to the lack of a current [post 18-years of age] evaluation from one of the aforementioned medical professionals.

In review, based on the clinical judgment of the state reviewing physician and the credible testimony of the Department's witness, I find that the Appellant has failed to preponderate his burden of proof. The necessary evaluation has not been performed and supporting evidence was not received by MDCH.

---

<sup>1</sup> This edition of the MPM is identical to the version in place at the time of the Appellant's appeal.

[REDACTED]  
Docket No. 2013-38787 PHR  
Decision and Order


The Department's decision to deny PA, based on this record was supported with sufficient evidence and the credible testimony of pharmacist Martini.

**DECISION AND ORDER**

The Administrative Law Judge, based on the above findings of fact and conclusions of law, decides that the Department properly denied the Appellant's request for PA of Adderall XR.

**IT IS THEREFORE ORDERED** that:

The Department's decision is AFFIRMED.



Robert J. Meade  
Administrative Law Judge  
for James K. Haveman, Director  
Michigan Department of Community Health

[REDACTED]  
cc: [REDACTED]

Dated Signed: 5/9/2013

Date Mailed: 5/10/2013

**\*\*\* NOTICE \*\*\***

The Michigan Administrative Hearing System may order a rehearing on either its own motion or at the request of a party within 30 days of the mailing date of this Decision and Order. The Michigan Administrative Hearing System will not order a rehearing on the Department's motion where the final decision or rehearing cannot be implemented within 90 days of the filing of the original request. The Appellant may appeal the Decision and Order to Circuit Court within 30 days of the receipt of the Decision and Order or, if a timely request for rehearing was made, within 30 days of the receipt of the rehearing decision.